Vincristine sulfate

别名: Leurocristine sulfate, NSC-67574 sulfate, 22-Oxovincaleukoblastine sulfate 中文名称：硫酸长春新碱

目录号：S1241 Purity: 99.94%

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。Vincristine sulfate可诱导凋亡。

Vincristine sulfate Chemical Structure

CAS: 2068-78-2

规格	价格	库存
10mM (1mL in DMSO)	734.41	现货
10mg	582.05	现货
50mg	2229.59	现货
200mg	7118.45	现货
1g	24324.3	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.94%

99.94

Vincristine sulfate相关产品

相关产品	Puromycin 2HCl Staurosporine (STS) Oligomycin A Geldanamycin Honokiol Geneticin (G418 Sulfate) STZ (Streptozotocin) Sodium Monensin (NSC 343257) Cephalomannine 10-Deacetylbaccatin-III Pirarubicin Hygromycin B Roxithromycin	点击展开
相关化合物库	激酶抑制剂库血管生成相关化合物库 TGF-beta/Smad信号通路库细胞骨架信号通路化合物库抗心血管疾病化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息(PMID)
H1299/ICAM-3	Cell Viability Assay	0-20 nM	96 h	inhibits cell viability dose dependently	24177012
NCI-H1299/pcDNA3	Cell Viability Assay	0-20 nM	96 h	inhibits cell viability dose dependently	24177012
Ramos	Apoptosis Assay	2 μM	48 h	induces 34.6%±1.92% apoptosis	24256491
CCD18Co	Growth Inhibition Assay	0-1000 nM	48 h	inhibits cell growth dose dependently	24403453
DLD-1	Growth Inhibition Assay	0-1000 nM	48 h	inhibits cell growth dose dependently	24403453
CCD18Co	Function Assay	100 nM	48 h	promotes RUNX3 demethylation	24403453
DLD-1	Function Assay	100 nM	48 h	promotes RUNX3 demethylation	24403453
U-251MG	Growth Inhibition Assay	0.1 μM	24/72 h	inhibits cell growth time dependently	24530235
A-172	Growth Inhibition Assay	0.1 μM	24/72 h	inhibits cell growth time dependently	24530235
SUDHL6	Function Assay	1 μM	72 h	induces significant apoptotic morphology changes cotrested with BCL11A siRNA	24961604
SUDHL6	Growth Inhibition Assay	1 μM	48/72 h	inhibits cell viability significantly	24961604
P12	Growth Inhibition Assay	1-3 nM	48 h	decreases viable cell numbers dose dependently	25156146
CEM	Growth Inhibition Assay	1-3 nM	48 h	decreases viable cell numbers dose dependently	25156146
Jurkat	Growth Inhibition Assay	1-3 nM	48 h	decreases viable cell numbers dose dependently	25156146
SK-MEL-28	Function Assay	30 nM	6 h	induces G2–M cell-cycle arrest	25313010
Raji	Function Assay	0.5 μM	72 h	abolishes autophagy	25446377
HepG2-HBV1.1	Growth Inhibition Assay	0.1 μM	12-72 h	induces cell cycle arrest at S-phase	25663769
HepG2-HBV1.1	Growth Inhibition Assay	0.1 μM	12-72 h	induces cell cycle arrest at S-phase	25663769
HepG2-HBV1.1	Growth Inhibition Assay	0.1 μM	1-5 d	inhibits the proliferation time dependently	25663769
HepG2-HBV1.1	Growth Inhibition Assay	0.1 μM	1-5 d	inhibits the proliferation time dependently	25663769
HepG2-HBV1.1	Function Assay	0.1 μM	48 h	promotes cell excretion of hepatitis B virus nucleocapsids instead of hepatitis B virus Dane particles	25663769
HepG2-HBV1.1	Function Assay	0.1 μM	24 h	promotes hepatitis B virus protein expression	25663769
HepG2.2.15	Function Assay	0.1 μM	24 h	promotes hepatitis B virus protein expression	25663769
HepG2-HBV1.1	Apoptosis Assay	0-0.5 μM	24 h	induces apoptosis dose dependently	25663769
HepG2.2.15	Cell Viability Assay	0-0.5 μM	24 h	decreases cell viability dose dependently	25663769
NCI-H1299/pcDNA3	Function Assay	1/5/10/20 nM	96 h	induces cleavage of caspases-3, 8, 9, and PARP	24177012
H1299/ICAM-3	Function Assay	1/5/10/20 nM	96 h	induces cleavage of caspases-3, 8, 9, and PARP	24177012
K562	Apoptosis Assay	0.3 μM	24 h	induces apoptosis significantly	24135937
K562/ADR	Apoptosis Assay	3 μM	24 h	induces apoptosis	24135937
K562	Cell Viability Assay	3.75–60 nM	72 h	inhibits cell viability dose dependently	23877223
lucena	Cell Viability Assay	3.75–60 nM	72 h	no effect	23877223
FEPS	Cell Viability Assay	3.75–60 nM	72 h	no effect	23877223
Jurkat	Apoptosis Assay	5 μg/ml	24 h	induces apoptosis significantly	23810409
Jurkat	Growth Inhibition Assay	5 μg/ml	24 h	arrest Jurkat cells in G2/M phase	23810409
SGC-7901	Growth Inhibition Assay	0-10 μg/ml	24/48/72 h	inhibits cell growth in dose and time dependent manner	23743572
SGC-7901/VCR	Growth Inhibition Assay	0-10 μg/ml	24/48/72 h	inhibits cell growth in dose and time dependent manner	23743572
JFCR39	Growth Inhibition Assay	1 µM	24 h	markedly increases the number of G2/M phase cells	23598276
A549	Function Assay	100 nM	16 h	leads to a loss of microtubules	23598276
SH-SY5Y	Growth Inhibition Assay	0.001-10 μM	24 h	IC50=0.113±0.012 μM	23129065
SH-SY5Y	Growth Inhibition Assay	0.001-10 μM	48 h	IC50=0.078±0.009 μM	23129065
SH-SY5Y	Growth Inhibition Assay	0.001-10 μM	72 h	IC50=0.051±0.008 μM	23129065
SH-SY5Y	Apoptosis Assay	0.1 μM	0-24 h	induces apoptosis of SH-SY5Y cells following cell cycle arrest at the G2/M phase	23129065
SH-SY5Y	Apoptosis Assay	0.1 μM	0-24 h	induces mitotic arrest	23129065
A549/EGFP	Growth Inhibition Assay	0.01-1000 μM		IC50=86.7 ± 29.1 μM	23634282
A549/Slug	Growth Inhibition Assay	0.01-1000 μM		IC50=9.7 ± 3.1 μM	23634282
HepG2	Growth Inhibition Assay		24 h	IC50=52.5 μM	24341688
TCC	Growth Inhibition Assay		48 h	IC50=50 nM	24716944
TCC	Growth Inhibition Assay		24 h	IC50=70 nM	24716944
LNCAP	Cytotoxicity assay		72 hrs	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay, IC50 = 0.0029 μM.	20732809
LNCAP	Cytotoxicity assay		72 hrs	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay, IC50 = 0.0061 μM.	23215348
PC3	Cytotoxicity assay		72 hrs	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay, IC50 = 0.011 μM.	20732809
PC3	Cytotoxicity assay		72 hrs	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay, IC50 = 0.015 μM.	23215348
PC3	Cytotoxicity assay		72 hrs	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0153 μM.	23489291
NFF	Cytotoxicity assay		72 hrs	Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0169 μM.	23489291
NFF	Cytotoxicity assay		72 hrs	Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay, IC50 = 0.017 μM.	23215348
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay, IC50 = 0.02 μM.	23215348
KB	Cytotoxicity assay		72 hrs	Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50 = 0.02 μM.	26522953
PC3	Antiproliferative assay		48 hrs	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 0.0276 μM.	28038323
HEK	Cytotoxicity assay		72 hrs	Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay, IC50 = 0.031 μM.	23215348
HeLa	Cytotoxicity assay		72 hrs	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0358 μM.	23489291
HeLa	Cytotoxicity assay		72 hrs	Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay, IC50 = 0.036 μM.	23215348
BT549	Antiproliferative assay		48 hrs	Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay, IC50 = 0.05472 μM.	28038323
DU145	Antiproliferative assay		48 hrs	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 0.0723 μM.	28038323
Leukemia cells	Antitumor assay		48 hrs	Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, GI50 = 0.1 μM.	19006285
Leukemia cells	Antitumor assay		48 hrs	Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, GI = 0.1 μM.	19006285
Colon cancer cells	Antitumor assay		48 hrs	Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, GI50 = 0.1 μM.	19006285
Colon cancer cells	Antitumor assay		48 hrs	Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, GI = 0.1 μM.	19006285
Leukemia cells	Growth inhibition assay		48 hrs	Growth inhibition of human leukemia cells after 48 hrs, GI50 = 0.1 μM.	20684599
Colon cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human colon cancer cells after 48 hrs, GI50 = 0.1 μM.	20684599
Leukemia cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human leukemia cells after 48 hrs, GI50 = 0.1 μM.	24747749
Colon cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human colon cancer cells after 48 hrs, GI50 = 0.1 μM.	24747749
Leukemia cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human leukemia cells after 48 hrs, GI50 = 0.1 μM.	22283430
Colon cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human COLON cells after 48 hrs, GI50 = 0.1 μM.	22283430
MDA-MB-231	Antiproliferative assay		48 hrs	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 0.1166 μM.	28038323
CNS	Antitumor assay		48 hrs	Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, GI50 = 0.12589 μM.	19006285
prostate cancer cells	Antitumor assay		48 hrs	Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, GI50 = 0.12589 μM.	19006285
CNS	Antitumor assay		48 hrs	Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, GI = 0.13 μM.	19006285
prostate cancer cells	Antitumor assay		48 hrs	Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, GI = 0.13 μM.	19006285
prostate cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human prostate cancer cells after 48 hrs, GI50 = 0.13 μM.	20684599
CNS	Growth inhibition assay		48 hrs	Growth inhibition of human CNS cancer cells after 48 hrs, GI50 = 0.13 μM.	20684599
CNS	Cytotoxicity assay		48 hrs	Cytotoxicity against human CNS cancer cells after 48 hrs, GI50 = 0.13 μM.	24747749
prostate cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human prostate cancer cells after 48 hrs, GI50 = 0.13 μM.	24747749
prostate cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human prostate cancer cells after 48 hrs, GI50 = 0.13 μM.	22283430
CNS	Cytotoxicity assay		48 hrs	Cytotoxicity against human CNS cancer cells after 48 hrs, GI50 = 0.13 μM.	22283430
Melanoma cells	Antitumor assay		48 hrs	Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, GI50 = 0.15849 μM.	19006285
Melanoma cells	Antitumor assay		48 hrs	Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, GI = 0.16 μM.	19006285
Melanoma cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human melanoma cells after 48 hrs, GI50 = 0.16 μM.	24747749
Melanoma cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human melanoma cells after 48 hrs, GI50 = 0.16 μM.	22283430
A549	Antiproliferative assay		48 hrs	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, IC50 = 0.1715 μM.	28038323
NSCLC	Antitumor assay		48 hrs	Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, GI = 0.25 μM.	19006285
NSCLC	Growth inhibition assay		48 hrs	Growth inhibition of human NSCLC cells after 48 hrs, GI50 = 0.25 μM.	20684599
NSCLC	Cytotoxicity assay		48 hrs	Cytotoxicity against human NSCLC cells after 48 hrs, GI50 = 0.25 μM.	22283430
NSCLC	Cytotoxicity assay		48 hrs	Cytotoxicity against human NSCLC cells after 48 hrs, GI50 = 0.25 μM.	24747749
NSCLC	Antitumor assay		48 hrs	Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, GI50 = 0.25119 μM.	19006285
ovarian cancer cells	Antitumor assay		48 hrs	Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM.	19006285
renal cancer cells	Antitumor assay		48 hrs	Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM.	19006285
breast cancer cells	Antitumor assay		48 hrs	Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM.	19006285
ovarian cancer cells	Antitumor assay		48 hrs	Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, GI = 0.32 μM.	19006285
renal cancer cells	Antitumor assay		48 hrs	Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, GI = 0.32 μM.	19006285
breast cancer cells	Antitumor assay		48 hrs	Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, GI = 0.32 μM.	19006285
renal cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human renal cancer cells after 48 hrs, GI50 = 0.32 μM.	20684599
breast cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human breast cancer cells after 48 hrs, GI50 = 0.32 μM.	20684599
ovarian cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human Ovarian cancer cells after 48 hrs, GI50 = 0.32 μM.	20684599
breast cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human breast cancer cells after 48 hrs, GI50 = 0.32 μM.	24747749
renal cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human renal cancer cells after 48 hrs, GI50 = 0.32 μM.	24747749
ovarian cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human ovarian cancer cells after 48 hrs, GI50 = 0.32 μM.	24747749
renal cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human renal cancer cells after 48 hrs, GI50 = 0.32 μM.	22283430
ovarian cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human ovarian cancer cells after 48 hrs, GI50 = 0.32 μM.	22283430
breast cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human breast cancer cells after 48 hrs, GI50 = 0.32 μM.	22283430
Lu1	Cytotoxicity assay		72 hrs	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay, IC50 = 0.48 μM.	26522953
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50 = 0.51 μM.	26522953
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay, IC50 = 0.69 μM.	26522953
COLON	Growth inhibition assay		48 hrs	Growth inhibition of human colon cancer cells after 48 hrs, TGI = 3.98 μM.	20684599
COLON	Cytotoxicity assay		48 hrs	Cytotoxicity against human colon cancer cells after 48 hrs, TGI = 3.98 μM.	24747749
COLON	Cytotoxicity assay		48 hrs	Cytotoxicity against human COLON cells after 48 hrs, TGI = 3.98 μM.	22283430
COLON	Antitumor assay		48 hrs	Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, TGI = 3.98107 μM.	19006285
CNS	Antitumor assay		48 hrs	Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, TGI = 6.30957 μM.	19006285
prostate cancer cells	Antitumor assay		48 hrs	Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, TGI = 6.30957 μM.	19006285
prostate cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human prostate cancer cells after 48 hrs, TGI = 6.31 μM.	20684599
CNS	Growth inhibition assay		48 hrs	Growth inhibition of human CNS cancer cells after 48 hrs, TGI = 6.31 μM.	20684599
CNS	Cytotoxicity assay		48 hrs	Cytotoxicity against human CNS cancer cells after 48 hrs, TGI = 6.31 μM.	24747749
prostate cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human prostate cancer cells after 48 hrs, TGI = 6.31 μM.	24747749
prostate cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human prostate cancer cells after 48 hrs, TGI = 6.31 μM.	22283430
CNS	Cytotoxicity assay		48 hrs	Cytotoxicity against human CNS cancer cells after 48 hrs, TGI = 6.31 μM.	22283430
Melanoma cells	Growth inhibition assay		48 hrs	Growth inhibition of human melanoma cells after 48 hrs, TGI = 7.94 μM.	20684599
breast cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human breast cancer cells after 48 hrs, TGI = 7.94 μM.	20684599
breast cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human breast cancer cells after 48 hrs, TGI = 7.94 μM.	24747749
Melanoma cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human melanoma cells after 48 hrs, TGI = 7.94 μM.	24747749
Melanoma cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human melanoma cells after 48 hrs, TGI = 7.94 μM.	22283430
breast cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human breast cancer cells after 48 hrs, TGI = 7.94 μM.	22283430
Melanoma cells	Antitumor assay		48 hrs	Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, TGI = 7.94328 μM.	19006285
breast cancer cells	Antitumor assay		48 hrs	Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, TGI = 7.94328 μM.	19006285
Leukemia cells	Antitumor assay		48 hrs	Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, TGI = 15.8489 μM.	19006285
NSCLC	Antitumor assay		48 hrs	Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, TGI = 15.8489 μM.	19006285
NSCLC	Growth inhibition assay		48 hrs	Growth inhibition of human NSCLC cells after 48 hrs, TGI = 15.85 μM.	20684599
Leukemia cells	Growth inhibition assay		48 hrs	Growth inhibition of human leukemia cells after 48 hrs, TGI = 15.85 μM.	20684599
NSCLC	Cytotoxicity assay		48 hrs	Cytotoxicity against human NSCLC cells after 48 hrs, TGI = 15.85 μM.	22283430
Leukemia cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human leukemia cells after 48 hrs, TGI = 15.85 μM.	24747749
NSCLC	Cytotoxicity assay		48 hrs	Cytotoxicity against human NSCLC cells after 48 hrs, TGI = 15.85 μM.	24747749
Leukemia cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human leukemia cells after 48 hrs, TGI = 15.85 μM.	22283430
renal cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human renal cancer cells after 48 hrs, TGI = 19.95 μM.	20684599
ovarian cancer cells	Growth inhibition assay		48 hrs	Growth inhibition of human Ovarian cancer cells after 48 hrs, TGI = 19.95 μM.	20684599
renal cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human renal cancer cells after 48 hrs, TGI = 19.95 μM.	24747749
ovarian cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human ovarian cancer cells after 48 hrs, TGI = 19.95 μM.	24747749
renal cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human renal cancer cells after 48 hrs, TGI = 19.95 μM.	22283430
ovarian cancer cells	Cytotoxicity assay		48 hrs	Cytotoxicity against human ovarian cancer cells after 48 hrs, TGI = 19.95 μM.	22283430
ovarian cancer cells	Antitumor assay		48 hrs	Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, TGI = 19.9526 μM.	19006285
renal cancer cells	Antitumor assay		48 hrs	Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, TGI = 19.9526 μM.	19006285
PC3	Cytotoxicity assay		48 hrs	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 28.11 μM.	29174816
HEK293/MRP1	Growth Inhibition Assay			IC50=0.055±0.0120 μM	24284783
HEK293/pcDNA3.1	Growth Inhibition Assay			IC50=0.004±0.0003 μM	24284783
MCF-7	Growth Inhibition Assay			IC50=0.0159±0.0062 μM	24704556
MCF-7/ADR	Growth Inhibition Assay			IC50=4.4826±0.2070 μM	24704556
HepG2	Growth Inhibition Assay			IC50=0.0115±0.0017 μM	24704556
HepG2/ADM	Growth Inhibition Assay			IC50=2.7863±0.2371 μM	24704556
HEK293/ABCC1	Growth Inhibition Assay			IC50=19.29 ± 2.08 nM	24726739
HEK293/pcDNA3.1	Growth Inhibition Assay			IC50=1.45 ± 0.20 nM	24726739
SW620/AD300	Growth Inhibition Assay			IC50=909.60 ± 8.91 nM	24726739
SW620	Growth Inhibition Assay			IC50=7.80 ± 0.08 nM	24726739
MCF-7-R	Cytotoxicity Assay			IC50=5.539 ± 0.144 nM	24858827
A549-R	Cytotoxicity Assay			IC50=12.178 ± 0.333 nM	24858827
MCF-7-R	Growth Inhibition Assay			IC50=5.539 ± 0.144 nM	24858827
MCF-7-WT	Growth Inhibition Assay			IC50=17.752 ± 0.218 nM	24858827
A549-R	Growth Inhibition Assay			IC50=12.178 ± 0.333 nM	24858827
A549-WT	Growth Inhibition Assay			IC50=19.437 ± 0.594 nM	24858827
SHSY5Y	Growth Inhibition Assay			IC50=8.2±0.6 nM	24921920
LAN1	Growth Inhibition Assay			IC50=2.3±0.2 nM	24921920
SKNAS	Growth Inhibition Assay			IC50=1.5±0.2 nM	24921920
IGNR91	Growth Inhibition Assay			IC50=24.3±1.7 nM	24921920
SKNBe2C	Growth Inhibition Assay			IC50=32.8±4.0 nM	24921920
HCT-116	Growth Inhibition Assay			GI50=5 nM	24927857
KBv200 (ABCB1)	Growth Inhibition Assay			IC50=0.3462 ± 0.0066 μM	25058526
KB	Growth Inhibition Assay			IC50=0.0049 ± 0.0001 μM	25058526
H157	Growth Inhibition Assay			IC50=1.03 ± 0.04 miu2M	25257911
W1	Growth Inhibition Assay			IC50=0.0032 μM	24140176
W1VR	Growth Inhibition Assay			IC50=0.056 μM	24140176
K562	Growth Inhibition Assay			IC50=0.032 ± 0.001 μM	24135937
K562/ADR	Growth Inhibition Assay			IC50=3.261 ± 0.412 μM	24135937
A549	Growth Inhibition Assay			IC50=0.10 ± 0.03 μM	23971075
A2780	Growth Inhibition Assay			IC50=3.5 mM	23829203
ACHN	Growth Inhibition Assay			IC50<0.1 mM	23829203
U-937	Growth Inhibition Assay			IC50<34 nM	23829203
Hep-2	Growth Inhibition Assay			IC50=0.04±0.01 μM	23780424
Hep-2/v	Growth Inhibition Assay			IC50=1.8±0.20 μM	23780424
SGC-7901	Apoptosis Assay			induces apoptosis significantly	23743572
SGC-7901/VCR	Apoptosis Assay			induces apoptosis significantly	23743572
KB-3-1	Growth Inhibition Assay			IC50=1.66 ± 0.162 μM	23673445
KB-C2	Growth Inhibition Assay			IC50=202.56 ± 42.481 μM	23673445
KB-3-1	Growth Inhibition Assay			IC50=1.26 ± 0.027 μM	23673445
KB-V1	Growth Inhibition Assay			IC50=208.85 ± 20.4 μM	23673445
HEK293/pcDNA3.1	Growth Inhibition Assay			IC50=24.1 ± 0.204 μM	23673445
HEK293/ABCB1	Growth Inhibition Assay			IC50=3512.8 ± 378.391 μM	23673445
SGC7901	Growth Inhibition Assay			IC50=1.26 ± 0.11 μg/ml	23564482
SGC7901/LV-NC	Growth Inhibition Assay			IC50=1.77 ± 0.16 μg/ml	23564482
SGC7901/LV-SGO1	Growth Inhibition Assay			IC50=4.36 ± 0.37 μg/ml	23564482
SGC7901/VCR	Growth Inhibition Assay			IC53=20.53 ± 1.96 μg/ml	23564482
SGC7901/VCR-NC	Growth Inhibition Assay			IC50=19.86 ± 2.01 μg/ml	23564482
SGC7901/VCR-si-SGO1	Growth Inhibition Assay			IC50=6.18 ± 1.03 μg/ml	23564482
SGC7901/ADR	Growth Inhibition Assay			IC50=7.85 ± 0.64 μg/ml	23564482
SGC7901/ADR-NC	Growth Inhibition Assay			IC50=8.93 ± 0.68 μg/ml	23564482
SGC7901/ADR-si-SGO1	Growth Inhibition Assay			IC50=3.46 ± 0.29 μg/ml	23564482
Colon cancer cells	Cytotoxicity assay			Cytotoxicity against human colon cancer cells, GI50 = 0.1 μM.	18598018
Leukemia cells	Cytotoxicity assay			Cytotoxicity against human leukemia cells, GI50 = 0.1 μM.	18598018
Leukemia cells	Antitumor assay			Antitumor activity against leukemia cells, GI50 = 0.1 μM.	17559205
Colon cancer cells	Antitumor assay			Antitumor activity against colon tumor cells, GI50 = 0.1 μM.	17559205
central nervous system cancer cells	Cytotoxicity assay			Cytotoxicity against human central nervous system cancer cells, GI50 = 0.12589 μM.	18598018
prostate cancer cells	Cytotoxicity assay			Cytotoxicity against human prostate cancer cells, GI50 = 0.12589 μM.	18598018
CNS	Antitumor assay			Antitumor activity against CNS tumor cells, GI50 = 0.12589 μM.	17559205
prostate cancer cells	Antitumor assay			Antitumor activity against prostate tumor cells, GI50 = 0.12589 μM.	17559205
Melanoma cells	Cytotoxicity assay			Cytotoxicity against human melanoma cells, GI50 = 0.15849 μM.	18598018
Melanoma cells	Antitumor assay			Antitumor activity against melanoma cells, GI50 = 0.15849 μM.	17559205
Melanoma cells	Growth inhibition assay			Growth inhibition of human melanoma cells after 48 hrs, GI50 = 0.16 μM.	20684599
NSCLC	Antitumor assay			Antitumor activity against NSCLC cells, GI50 = 0.25119 μM.	17559205
Non-small cell lung carcinoma cells	Cytotoxicity assay			Cytotoxicity against human Non-small cell lung carcinoma cells, GI50 = 0.25119 μM.	18598018
ovarian cancer cells	Cytotoxicity assay			Cytotoxicity against human ovarian cancer cells, GI50 = 0.31623 μM.	18598018
renal cancer cells	Cytotoxicity assay			Cytotoxicity against human renal cancer cells, GI50 = 0.31623 μM.	18598018
breast cancer cells	Cytotoxicity assay			Cytotoxicity against human breast cancer cells, GI50 = 0.31623 μM.	18598018
renal cancer cells	Antitumor assay			Antitumor activity against renal tumor cells, GI50 = 0.31623 μM.	17559205
ovarian cancer cells	Antitumor assay			Antitumor activity against ovarian tumor cells, GI50 = 0.31623 μM.	17559205
breast cancer cells	Antitumor assay			Antitumor activity against breast tumor cells, GI50 = 0.31623 μM.	17559205
COLON	Cytotoxicity assay			Cytotoxicity against human colon cancer cells, TGI = 3.98107 μM.	18598018
COLON	Antitumor assay			Antitumor activity against colon tumor cells, TGI = 3.98107 μM.	17559205
central nervous system cancer cells	Cytotoxicity assay			Cytotoxicity against human central nervous system cancer cells, TGI = 6.30957 μM.	18598018
prostate cancer cells	Cytotoxicity assay			Cytotoxicity against human prostate cancer cells, TGI = 6.30957 μM.	18598018
CNS	Antitumor assay			Antitumor activity against CNS tumor cells, TGI = 6.30957 μM.	17559205
prostate cancer cells	Antitumor assay			Antitumor activity against prostate tumor cells, TGI = 6.30957 μM.	17559205
Melanoma cells	Cytotoxicity assay			Cytotoxicity against human melanoma cells, TGI = 7.94328 μM.	18598018
breast cancer cells	Cytotoxicity assay			Cytotoxicity against human breast cancer cells, TGI = 7.94328 μM.	18598018
Melanoma cells	Antitumor assay			Antitumor activity against melanoma cells, TGI = 7.94328 μM.	17559205
breast tumor cells	Antitumor assay			Antitumor activity against breast tumor cells, TGI = 7.94328 μM.	17559205
NSCLC	Antitumor assay			Antitumor activity against NSCLC cells, TGI = 15.8489 μM.	17559205
Non-small cell lung carcinoma cells	Cytotoxicity assay			Cytotoxicity against human Non-small cell lung carcinoma cells, TGI = 15.8489 μM.	18598018
Leukemia cells	Cytotoxicity assay			Cytotoxicity against human leukemia cells, TGI = 15.8489 μM.	18598018
Leukemia cells	Antitumor assay			Antitumor activity against leukemia cells, TGI = 15.8489 μM.	17559205
ovarian cancer cells	Cytotoxicity assay			Cytotoxicity against human ovarian cancer cells, TGI = 19.9526 μM.	18598018
renal cancer cells	Cytotoxicity assay			Cytotoxicity against human renal cancer cells, TGI = 19.9526 μM.	18598018
renal tumor cells	Antitumor assay			Antitumor activity against renal tumor cells, TGI = 19.9526 μM.	17559205
ovarian tumor cells	Antitumor assay			Antitumor activity against ovarian tumor cells, TGI = 19.9526 μM.	17559205
neural precursor cells	Function assay			Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	17417631
点击查看更多细胞系数据

生物活性

产品描述

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。Vincristine sulfate可诱导凋亡。

靶点

Microtubules ^[1]
(Cell-free assay)

32 μM

体外研究(In Vitro)
体外研究活性	Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用，K_i为85 nM。^[1]在低浓度时，Vincristine抑制纺锤体，使染色体分离失败，进而导致中期停滞，并抑制有丝分裂。在较高浓度时，Vincristine可能干扰且诱导全部微管解聚。^[2] Vincristine 诱导肿瘤细胞凋亡，且抑制SH-SY5Y细胞增殖，IC50为0.1 µM。Vincristine诱导有丝分裂停滞，促进caspase-3和-9及cyclin B的表达，但降低cyclin D的表达。^[3] Vincristine通过干扰微管功能而诱导神经毒性形成，这会导致轴突运输堵塞，从而导致轴突变性。^[4]
细胞实验	细胞系	B16 黑色素瘤细胞
	浓度	10 nM
	孵育时间	3 天
	方法	细胞按5 × 10⁴ cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上，在37°C下含5% CO₂ 和95% 空气的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基，继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后，每天使用库氏计数器完成细胞计数
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1		26156322
	Growth inhibition assay	Cell viability		26156322

体内研究(In Vivo)
体内研究活性	Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠，平均生长延迟120天和52天以上，且再植指数分别为0.06％和5％。^[5] Vincristine 处理小鼠，通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量，降低近75%。^[6]
动物实验	Animal Models	携带人类横纹肌肉瘤移植瘤Rh12的鼠
	Dosages	3 mg/kg
	Administration	腹腔注射

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT05844670	Recruiting	Pediatric Cancer	Moi University\|Princess Maxima Center for Pediatric Oncology\|Amsterdam UMC location VUmc	April 20 2023	Phase 4
NCT04448834	Withdrawn	B-cell Acute Lymphoblastic Leukemia	Dorothy Sipkins MD PhD\|Amgen\|Acrotech Biopharma Inc.\|Duke University	January 2022	Phase 2

参考文献
https://pubmed.ncbi.nlm.nih.gov/3986806/ https://pubmed.ncbi.nlm.nih.gov/10226730/ https://pubmed.ncbi.nlm.nih.gov/23129065/ https://pubmed.ncbi.nlm.nih.gov/558047/ https://pubmed.ncbi.nlm.nih.gov/3190743/ https://pubmed.ncbi.nlm.nih.gov/1827725/ + 展开

参考文献

https://pubmed.ncbi.nlm.nih.gov/3986806/
https://pubmed.ncbi.nlm.nih.gov/10226730/
https://pubmed.ncbi.nlm.nih.gov/23129065/

https://pubmed.ncbi.nlm.nih.gov/558047/
https://pubmed.ncbi.nlm.nih.gov/3190743/
https://pubmed.ncbi.nlm.nih.gov/1827725/

+ 展开

化学信息&溶解度

分子量	923.04	分子式	C₄₆H₅₈N₄O₁₄S
CAS号	2068-78-2	SDF	Download Vincristine sulfate SDF
Smiles	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 100 mg/mL ( (108.33 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 100 mg/mL (108.33 mM)

Ethanol : Insoluble

DMSO : 100 mg/mL ( (108.33 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 100 mg/mL (108.33 mM)

Ethanol : Insoluble

DMSO : 185 mg/mL ( (200.42 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 185 mg/mL (200.42 mM)

Ethanol : Insoluble

DMSO : 100 mg/mL ( (108.33 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : 50 mg/mL (54.16 mM)

Ethanol : Insoluble

DMSO : 100 mg/mL ( (108.33 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 6 mg/mL (6.5 mM)

Water : Insoluble

摩尔浓度计算器

体内溶解配方批次：现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂				动物体内配方计算器
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

常见问题及建议解决方法

问题 1:
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

回答：
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):